Xeris Biopharma Holdings, Inc. (XERS) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Xeris Biopharma is a commercial-stage biopharmaceutical company focused on therapies for chronic endocrine and neurological diseases. Its primary commercial products are Recorlev (Cushing's syndrome), Gvoke (severe hypoglycemia), and Keveyis (Primary Periodic Paralysis). The company is also advancing XP-8121, a once-weekly subcutaneous levothyroxine candidate.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6 Months 2026 | 6 Months 2025 |
|---|---|---|---|---|
| Total Revenue | $92,100 | $71,539 | $175,227 | $131,658 |
| Net Loss | $(31,101) | $(1,928) | $(28,867) | $(11,148) |
| Operating Income | $5,173 | $4,482 | $13,089 | $1,392 |
| Cash from Operations (6mo) | $18,133 (vs. $(9,849) prior year) | |||
| Cash & Equivalents (End of Period) | $121,747 | |||
| Total Debt (Net) | $252,590 |
Margins: Gross margin on product revenue improved to approximately 86.3% for the six months ended June 30, 2026, compared to 83.4% in the prior year period, driven by favorable product mix.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 28.7% quarter-over-quarter and 33.1% year-over-year (six months). This was primarily driven by Recorlev, which saw an 80.6% increase in Q2 revenue due to higher patient demand and favorable pricing.
- Net Loss Expansion: The net loss widened significantly to $31.1 million in Q2 2026 from $1.9 million in Q2 2025. This was largely due to a $30.8 million loss on debt extinguishment related to the settlement of 2028 Convertible Notes.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 37.5% quarter-over-quarter to $61.0 million, primarily due to increased personnel costs to support commercial expansion. R&D expenses increased 32.5% to $10.7 million.
- Debt Restructuring: In June 2026, the company executed an exchange agreement for $23.0 million of its 2028 Convertible Notes. By July 2026, all 2028 Convertible Notes were settled via a combination of cash and stock issuance.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash resources ($121.7 million) are sufficient to fund operations for at least the next twelve months. However, the company expects to incur net losses in the near term.
- Outlook: The company is focused on maximizing the potential of its three commercial products and advancing the Phase 3-ready pipeline candidate XP-8121. It is also pursuing formulation partnerships.
- Legal Contingencies: The company filed patent infringement lawsuits against multiple ANDA filers (Torrent, Somerset, Sandoz, Zydus, Novitium) regarding generic versions of Recorlev. These lawsuits have triggered an automatic stay of FDA approval for the generic products until up to June 30, 2029, pending a bench trial tentatively scheduled for November 2028.
- Risks: Key risks include the outcome of patent litigation, the ability to secure future financing, and the success of commercialization efforts for Recorlev, Gvoke, and Keveyis.
Investor Verification Checklist
- Debt Settlement Impact: Verify the full details of the $30.8 million debt extinguishment loss and the remaining debt obligations under the 2029 Loan Agreement ($200 million principal).
- Recorlev Growth Sustainability: Assess whether the 80%+ revenue growth in Recorlev is sustainable given the upcoming patent litigation trial in 2028 and potential generic entry.
- Cash Burn Rate: Monitor the trajectory of operating cash flow, which turned positive ($18.1M) in the first half of 2026, against the backdrop of high SG&A spending.
- Inventory Levels: Review the increase in inventory to $80.9 million and the associated reserves ($13.7 million) to ensure no significant write-downs are pending.
- Dilution: Note the issuance of approximately 8.6 million shares in July 2026 to settle the 2028 Convertible Notes, which impacts share count and future earnings per share.